|
| Press Releases |
|
 |
|
| Thursday, March 23, 2023 |
|
|
Eisai to Present New Lecanemab Data, Including Research Evaluating Safety Profile, Clinical Outcomes and Quality of Life Measures, as Well as Other Important Alzheimer's Disease Research, at the AD/PD 2023 Annual Meeting |
| Eisai Co., Ltd. announced today the company will present the latest findings on lecanemab (generic name, U.S. brand name: LEQEMBI), Eisai's anti-amyloid beta (Aβ) protofibril* antibody for the treatment of Alzheimer's disease (AD), at the 2023 International Conference on Alzheimer's and Parkinson's Diseases and related neurological disorders (AD/PD). more info >> |
|
| Monday, March 20, 2023 |
|
|
Eisai Publishes Societal Value of Lecanemab Using Phase 3 Clarity AD Data in Peer-Reviewed Neurology and Therapy Journal |
| Eisai Co., Ltd. today announced the publication of updated results from an evaluation estimating the societal value of anti-amyloid-beta (Aβ) protofibril antibody lecanemab (generic name, U.S. brand name: LEQEMBI) in people living with mild cognitive impairment (MCI) due to Alzheimer's disease (AD) and mild AD (collectively known as early AD). more info >> |
|
| Tuesday, March 14, 2023 |
|
|
U.S. Veterans' Health Administration (VHA) Provides Coverage of LEQEMBI (lecanemab-Irmb) Two Months After LEQEMBI's FDA Accelerated Approval for Veterans Living with Early Stages of Alzheimer's Disease |
| Eisai Co., Ltd. announced today that the U.S. Veterans' Health Administration (VHA) is providing coverage of LEQEMBI (lecanemab-irmb) to veterans living with early stages of Alzheimer's disease (AD). VHA healthcare professionals meeting the criteria set forth by the VHA can prescribe LEQEMBI to veterans who fit the VHA's criteria and the U.S. Food and Drug Administration's (FDA) current label. more info >> |
|
| Friday, March 10, 2023 |
|
|
Eisai Receives the "Basic Achievement Grand Prize" at the 2023 J-Win Diversity Award |
| Eisai Co., Ltd. announced today that it was selected as the winner of the "Basic Achievement Grand Prize" at the "2023 J-Win Diversity Award" held by non-profit organization Japan Women's Innovative Network (NPO J-Win). more info >> |
|
| Thursday, March 9, 2023 |
|
|
Eisai Certified as a 2023 Health and Productivity Management Outstanding |
| Eisai Co., Ltd. announced today that it has been certified as a Health and Productivity Management Outstanding Organization in the large enterprise category (White 500) by Japan's Ministry of Economy, Trade and Industry and the Nippon Kenko Kaigi. more info >> |
|
| Monday, March 6, 2023 |
|
|
FDA Accepts Eisai's Filing of a Supplemental Biologics License Application and Grants Priority Review for Traditional Approval of LEQEMBITM (lecanemab-irmb) for the Treatment of Alzheimer's Disease |
| Eisai Co., Ltd. and Biogen Inc. announced today that the U.S. Food and Drug Administration (FDA) has accepted Eisai's supplemental Biologics License Application (sBLA) for LEQEMBITM (lecanemab-irmb) 100 mg/mL injection for intravenous use, supporting the conversion of the accelerated approval of LEQEMBI to a traditional approval. more info >> |
|
| Thursday, March 2, 2023 |
|
|
Biogen Japan and Eisai Provide Update on Co-Promotion Of Multiple Sclerosis Treatments In Japan |
| Biogen Japan Ltd. and Eisai Co., Ltd. announced today the termination of the co-promotion agreement that has been in place since January 2018 for Biogen Japan's multiple sclerosis (MS) treatments TECFIDERA (dimethyl fumarate), TYSABRI (natalizumab, genetic recombinant) and AVONEX (interferon beta 1a, genetic recombinant) in Japan as of March 31, 2023. more info >> |
|
| Tuesday, February 28, 2023 |
|
|
Biologics License Application for Lecanemab Designated for Priority Review by China National Medical Products Administration |
| Eisai Co., Ltd. and Biogen Inc. announced today that the Biologics License Application (BLA) for lecanemab, an investigational anti-amyloid beta (Abeta) protofibril antibody, has been designated for Priority Review by the National Medical Products Administration (NMPA) in China. more info >> |
|
| Tuesday, February 21, 2023 |
|
|
Dissolution of Bracco-Eisai Joint Venture |
| Bracco Imaging S.p.A. and Eisai Co., Ltd. announced today that the joint venture regarding the company Bracco-Eisai Co., Ltd. (Ratio of Shares Held: Bracco 51% Eisai 49%), will be dissolved as of March 31, 2023. more info >> |
|
| Monday, January 30, 2023 |
|
|
Lecanemab Receives Priority Review Status in Japan |
| Eisai Co., Ltd. and Biogen Inc. announced today that an application for manufacturing and marketing approval for lecanemab (generic name, U.S. brand name: LEQEMBI), an anti-amyloid-beta (Abeta) protofibril* antibody, in Japan has been designated for Priority Review by the Japanese Ministry of Health, Labour and Welfare (MHLW). more info >> |
|
|
|
|
|
|
|
|
 |
| Latest Press Releases |
|
OBI Pharma and TegMine Therapeutics Sign Exclusive Global License Agreement for Glycan-Targeting ADC
Jan 12, 2026 20:00 HKT/SGT
|
|
|
Charlie's Holdings (OTCQB:CHUC) Signs Agreement with IKE Tech to Commercialize Transformational Age-Gated Vapes that Will Address FDA Concerns Related to Youth Access
Jan 12, 2026 19:00 HKT/SGT
|
|
|
Toys & Games Fair, Baby Products Fair and Stationery & School Supplies Fair open today
Jan 12, 2026 18:26 HKT/SGT
|
|
|
Mazda Unveils MAZDA CX-6e New Battery EV in World Premiere
Jan 12, 2026 13:10 JST
|
|
|
Argentine Football Association (AFA) teams with Verofax to offer AI Experiences to Fans 
Jan 12, 2026 10:00 HKT/SGT
|
|
|
Metaspacex Limited Partners with Popcorn Technology to Expand into Web3.0 Digital Finance
Jan 11, 2026 20:59 HKT/SGT
|
|
|
PromiCell, Inc. presents during JP Morgan's 2026 Healthcare Conference
Jan 10, 2026 07:00 HKT/SGT
|
|
|
TOYOTA GAZOO Racing Announces GR Yaris MORIZO RR
Jan 9, 2026 16:03 JST
|
|
|
Honda Announces New Lines of Models that Represent "Honda Sports DNA" at Tokyo Auto Salon 2026
Jan 9, 2026 14:24 JST
|
|
|
Honda Launches Fixed-Battery Electric Two-Wheeled Personal Commuter "Honda UC3" in Thailand and Vietnam
Jan 9, 2026 13:27 JST
|
|
|
Sponsorship Agreement Reached with LCR Honda; Full-Season MotoGP Entry as Pro Honda LCR
Jan 9, 2026 13:05 JST
|
|
|
Mazda Develops New Body Color, "Navy Blue Mica"
Jan 9, 2026 10:23 JST
|
|
|
Fujitsu develops digital learning platform for JAL to support self-directed learning and training management
Jan 9, 2026 10:07 JST
|
|
|
Capital Margin Trade Announces the Launch of Practical Trading Tools Designed For Structured Market Execution
Jan 9, 2026 07:00 HKT/SGT
|
|
|
Military Metals Announces Buyback of 1% Royalty on Slovakian Portfolio
Jan 8, 2026 20:59 HKT/SGT
|
|
|
|
|
More Press release >> |
|
|
|
|
|
|
|
